Abivax SA Sponsored ADR (ABVX) has released an update.
Abivax SA, a biotech firm focusing on therapeutics for chronic inflammatory diseases, has announced its general meeting on May 30, 2024, with preparatory documents now available to shareholders. The company’s lead drug candidate, obefazimod, has shown promise in Phase 2 trials and is progressing to a pivotal global Phase 3 trial for ulcerative colitis treatment, with a Phase 2b trial for Crohn’s disease expected to commence in Q3 2024.
For further insights into ABVX stock, check out TipRanks’ Stock Analysis page.